NCT06704672
Clinical Study to Evaluate the Impact of the Accu-Chek SmartGuide CGM Solution on the Mean Change in Time in Range Compared With Self-Monitoring of Blood Glucose in Participants With Type 1 and Type 2 Diabetes Mellitus
StatusActive, Not Recruiting
PhaseNot applicable
SponsorHoffmann-La Roche
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Oct 27, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
All 27 versions: 19 with changes below, 8 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Enrollment closed, study ongoing
- Primary completion pushed from Nov 15, 2026 to Jan 15, 2027
- Study completion pushed from May 30, 2027 to Jul 15, 2027
- Study sites: 19 to 20
- Notable Eligibility criteria expanded, about 25 words
- Primary endpoints: details revised at 1 of 1 entry
- Secondary endpoints: details revised at 9 of 21 entries
- Minor Study sites: 18 to 19v24
- Minor Primary completion pushed from Jun 15, 2026 to Nov 15, 2026
- Study completion pushed from Dec 31, 2026 to May 30, 2027
- Minor Study sites: 16 to 18v21
Show 13 earlier versionsHide 13 earlier versions
- Minor Study sites: 14 to 16v20
- Minor Study sites: 13 to 14v18
- Minor Study sites: 12 to 13v17
- Minor Study sites: 11 to 12
- Primary completion date: Jan 3, 2026 to Jun 15, 2026
- Study completion date: May 30, 2026 to Dec 31, 2026
- Minor Study sites: 9 to 11v14
- Minor Study sites: 6 to 9v13
- Minor Study sites: 5 to 6
- Primary completion date: Oct 18, 2025 to Jan 3, 2026
- Study completion date: Mar 14, 2026 to May 30, 2026
- Minor Study sites: 4 to 5v9
- Minor Study sites: 3 to 4v8
- Minor Study sites: 2 to 3
- Primary completion date: Sep 30, 2025 to Oct 18, 2025
- Study completion date: Feb 15, 2026 to Mar 14, 2026
- Start date changed from estimate of Mar 30, 2025 to Apr 14, 2025
Notable Trial status: Not Yet Recruiting to Recruitingv6 Show 4 more changesShow less
- Study sites: 0 to 2
- Primary completion date: Sep 15, 2025 to Sep 30, 2025
- Study completion date: Feb 1, 2026 to Feb 15, 2026
- Start date: Mar 15, 2025 to Mar 30, 2025
- Minor Primary completion date: Jun 30, 2025 to Sep 15, 2025
- Study completion date: Oct 1, 2025 to Feb 1, 2026
- Start date: Feb 15, 2025 to Mar 15, 2025
- Notable Start date: Dec 15, 2024 to Feb 15, 2025v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Change in the Percentage of Time in Range of a Blood Glucose Concentration of 70 to 180 mg/dL from the Baseline Period to Assessment Period A
Timeframe: Baseline Period (Weeks 1 and 2) and Assessment Period A (Weeks 5 and 6)
Secondary (21)
Change in the Percentage of Time in Range of a Blood Glucose Concentration of 70 to 180 mg/dL from the Baseline Period to Assessment Period B
Change in the Percentage of Time in Range of a Blood Glucose Concentration of 70 to 180 mg/dL from the Baseline Period to Assessment Period C
Percentage of Time in Tight Range of a Blood Glucose Concentration of 70 to 140 mg/dL by Study Period
Percentage of Time Above Range (Blood Glucose Concentration of >180 to ≤250 mg/dL) in Level 1 Hyperglycemia by Study Period
Percentage of Time Above Range (Blood Glucose Concentration >250 mg/dL) in Level 2 Hyperglycemia by Study Period
Show 16 moreShow less
Percentage of Time Below Range (Blood Glucose Concentration of ≥54 to <70 mg/dL) in Level 1 Hypoglycemia by Study Period
Percentage of Time Below Range (Blood Glucose Concentration <54 mg/dL) in Level 2 Hypoglycemia by Study Period
Number of Level 1 Hypoglycemia Events by Study Period
Number of Level 2 Hypoglycemia Events by Study Period
Average Glucose Management Indicator, as an Estimate of HbA1c, by Study Period
Average Blood Glucose Concentration by Study Period
Average Glycemic Variability in Blood Glucose Concentration by Study Period
Average HbA1c Values from the Central Laboratory
Average Daily Insulin Dose
Average Number of Daily Insulin Boluses Injected
Average Daily Amount of Carbohydrates Consumed
Hypoglycemia Fear Survey-II (HFS-II) Score at Specified Timepoints
Diabetes Distress Scale 17 (DDS-17) Questionnaire Score at Specified Timepoints
Ecological Momentary Assessment (EMA) Questionnaire Score at Specified Timepoints
Number of Participants by Their Responses to the Roche Diabetes Care SmartGuide Usability Questionnaire (Group A Only)
Number of Healthcare Providers (HCP) by Their Responses to the Roche Diabetes Care HCP Accu-Chek Care Questionnaire
Arms and interventions
Group A: Accu-Chek SmartGuide CGM SolutionExperimental
Group B: Self-Monitoring of Blood Glucose (SMBG)Other
Devices: Accu-Chek SmartGuide CGM Solution, Accu-Chek SmartGuide Sensor and Blinded Apps, SMBG Device
Sites
19 sites in 2 countries
Poland 10, Turkey (Türkiye) 9